ArticleCancer communications (London, England)2022

A novel histone deacetylase inhibitor exerts promising anti-breast cancer activity via triggering AIFM1-dependent programmed necrosis.

Peipei Shan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.